Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL

Enrollment

271

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions

Age-related Macular Degeneration

Interventions

DRUG

AGN-150998

AGN-150998 Intravitreal injection.

DRUG

ranibizumab

Ranibizumab 0.5 mg given by intravitreal injection.

OTHER

Sham Injection

Stage 3: Sham injection at Weeks 12 and 16.

Trial Locations (8)

Phoenix

Sydney

Vienna

Créteil

Bonn

Tel Aviv

Florence

Binningen